Abstract

GISSI-Prevenzione was conceived as a population, pragmatic trial on patients with recent myocardial infarction conducted in the framework of the Italian public health system. In GISSI-Prevenzione, patients were invited to follow Mediterranean dietary habits, and were treated with up-to-date preventive pharmacological interventions. Long-term n-3 PUFA 1 g daily, but not vitamin E 300 mg daily, was beneficial for death and for combined death, non-fatal myocardial infarction, and stroke. All the benefit, however, was attributable to the decrease in risk for overall, cardiovascular, cardiac, coronary, and sudden death.

At variance from the orientation of a scientific scenario largely dominated by the ‘cholesterol-heart hypothesis’, GISSI-Prevenzione results indicate n-3 PUFA (virtually devoid of any cholesterol-lowering effect) as a relevant pharmacological treatment for secondary prevention after myocardial infarction.

As to the relevance and comparability of GISSI-Prevenzione results, up to 5·7 lives could be saved per 1000 patients with previous myocardial infarction treated with n-3 PUFA (1 g daily) per year. Such a result is comparable to that observed in the LIPID trial, where 5·2 lives could be saved per 1000 hypercholaesterolemic, CHD patients treated with pravastatin for 1 year.

The choice in favour of a relatively low-dose regimen (1 g capsule daily) more acceptable for long-term treatment in a population of patients following Mediterranean dietary habits, the pattern of effects seen in GISSI-Prevenzione (namely, reduction of overall mortality with no decrease in the rate of non-fatal myocardial infarction), all suggest that it can confidently be said that n-3 PUFA treatment should be considered a recommended new component of secondary prevention. The importance of this combined/additive effect is further suggested by the preliminary analyses (to be submitted in the final form for publication) of the interplay between diet and n-3 PUFA: there is an interesting direct correlation between size of the effect and ‘correctness’ of background diets. It can be anticipated that a conceptual barrier must be overcome: a ‘dietary drug’ should be added to ‘dietary advice’, which remains fundamental to allow this statement to become true in clinical practice.

on behalf of the GISSI-Prevenzione investigators

*
The names of GISSI-Prevenzione investigators are reported in Reference 63.

References

[1]
Simopoulos
AP
. Omega-3 fatty acids in health and disease and growth and development.
Am J Clin Nutr
 .
1991
;
54
:
438
–463
[2]
Simopoulos
AP
. ω3 fatty acids in the prevention-management of cardiovascular disease.
Can J Physiol Pharmacol
 .
1997
;
75
:
234
–239
[3]
Bang
HO
, Dyerberg J, Hjørne N. The composition of food consumed by Greenland Eskimos.
Acta Med Scand
 .
1976
;
200
:
69
–73
[4]
Ascherio
A
, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake and the risk of coronary disease among men.
N Engl J Med
 .
1995
;
332
:
977
–982
[5]
Albert
CM
, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death.
J Am Med Assoc
 .
1998
;
279
:
23
–28
[6]
Kromhout
D
, Bosschieter EB, de Lezenne CC. The inverse relationship between fish consumption and 20-year mortality from coronary heart disease.
N Engl J Med
 .
1985
;
312
:
1205
–1209
[7]
Daviglus
ML
, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction.
N Engl J Med
 .
1997
;
336
:
1046
–1053
[8]
Dolecek
TA
. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial. Proc Soc Exp Biol Med. 1992. p. 177–182
[9]
Rodriguez
BL
, Sharp DS, Abbott RD, et al. Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers: The Honolulu Heart Program.
Circulation
 .
1996
;
94
:
952
–956
[10]
De Lorgeril
M
, Salen P, Martin J-L, Moniaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.
Circulation
 .
1999
;
99
:
779
–785
[11]
Singh
RB
, Rastogi SS, Verma R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up.
Br Med J
 .
1992
;
304
:
1015
–1019
[12]
Albert
CM
, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death.
J Am Med Assoc
 .
1998
;
279
:
23
–28
[13]
Ascherio
A
, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake and the risk of coronary disease among men.
N Engl J Med
 .
1995
;
332
:
977
–982
[14]
Kromhout
D
, Bosschieter EB, de Lezenne CC. The inverse relationship between fish consumption and 20-year mortality from coronary heart disease.
N Engl J Med
 .
1985
;
312
:
1205
–1209
[15]
Daviglus
ML
, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction.
N Engl J Med
 .
1997
;
336
:
1046
–1053
[16]
Dolecek
TA
. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial. Proc Soc Exp Biol Med. 1992. p. 177–182
[17]
Rodriguez
BL
, Sharp DS, Abbott RD, et al. Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers: The Honolulu Heart Program.
Circulation
 .
1996
;
94
:
952
–956
[18]
De Lorgeril
M
, Salen P, Martin J-L, Moniaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.
Circulation
 .
1999
;
99
:
779
–785
[19]
Singh
RB
, Rastogi SS, Verma R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up.
Br Med J
 .
1992
;
304
:
1015
–1019
[20]
Singh
RB
, Niaz MA, Sharma JP, et al. Randomized, double-blind placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian Experiment of Infarct Survival-4.
Cardiovasc Drug Ther
 .
1997
;
11
:
485
–491
[21]
von Shacky
C
, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med
 .
1999
;
130
:
554
–562
[22]
Burr
ML
, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART).
Lancet
 .
1989
;
ii
:
757
–761
[23]
Harris
WS
. n-3 fatty acids and serum lipoproteins: human studies.
Am J Clin Nutr
 .
1997
;
65
(Suppl 5):
1645S
–1654S
[24]
Harris
WS
. n-3 fatty acids and serum lipoproteins: animal studies.
Am J Clin Nutr
 .
1997
;
65
(Suppl 5):
1611S
–1616S
[25]
McLennan
PL
, Bridle TM, Abeywardena MY, Charnok JS. Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey.
Am Heart J
 .
1992
;
123
:
1555
–1561
[26]
McLennan
PL
. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rats.
Am J Clin Nutr
 .
1993
;
57
:
207
–212
[27]
Kang
JX
, Leaf A. Antiarrhythmic effects of polyunsaturated fatty acids: recent studies.
Circulation
 .
1996
;
94
:
1774
–1780
[28]
Billman
GE
, Kang JX, Leaf A. Prevention of ischemia-induced ventricular arrhythmias by dietary pure n-3 polyunsaturated fatty acids in dogs.
Circulation
 .
1999
;
99
:
2452
–2457
[29]
Sellmayer
A
, Witzgall H, Lorenz RL, Weber PC. Effects of dietary fish oil on ventricular premature complexes.
Am J Cardiol
 .
1995
;
76
:
974
–977
[30]
Christensen
JH
, Gustenhoff P, Eilersen E, et al. n-3 fatty acids and ventricular extra systoles in patients with ventricular tachyarrhythmias.
Nutr Res
 .
1995
;
15
:
1
–8
[31]
Christensen
JH
, Korup E, Aaroe J, et al. Fish consumption, ω3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction.
Am J Cardiol
 .
1997
;
79
:
1670
–1673
[32]
Siscovick
DS
, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain ω3 polyunsaturated fatty acids and the risk of primary cardiac arrest.
J Am Med Assoc
 .
1995
;
274
:
1363
–1367
[33]
Kang
JX
, Leaf A. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proc Natl Acad Sci USA. 1994. p. 9886–9890
[34]
Kang
JX
, Leaf A. Prevention and termination of the β-adrenergic agonist-induced arrhythmias by free polyunsaturated fatty acids in neonatal rat cardiac myocytes.
Biochem Biophys Res Commun
 .
1995
;
208
:
629
–636
[35]
Kang
JX
, Xiao Y-F, Leaf A. Free, long-chain, polyunsaturated fatty acids reduce membrane electrical excitability in neonatal rat cardiac myocytes. Proc Natl Acad Sci USA. 1995. p. 3997–4001
[36]
Kang
JX
, Xiao Y-F, Leaf A. Free, long-chain, polyunsaturated fatty acids reduce membrane electrical excitability in neonatal rat cardiac myocytes. Proc Natl Acad Sci USA. 1995. p. 3997–4001
[37]
Xiao
Y-F
, Kang JX, Morgan JP, Leaf A. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci USA. 1995. p. 1100–1104
[38]
Xiao
Y-F
, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat cardiac myocytes. Proc Natl Acad Sci USA. 1997. p. 4182–4187
[39]
Xiao
Y-F
, Wright SN, Wang JK, Morgan JP, Leaf A. n-3 fatty acids suppress voltage-gated Na+ currents in HEK293t cells transfected with the (subunit of the human cardiac Na+ channel. Proc Natl Acad Sci USA. 1998. p. 2680–2685
[40]
Marchioli
R
. Di Pasquale A per i Ricercatori GISSI-Prevenzione. Il quadro di riferimento biochimico, farmacologico, epidemiologico del GISSI-Prevenzione.
G Ital Cardiol
 .
1993
;
23
:
933
–964
[41]
Gruppo Italiano Studio sulla Sopravvivenza nell'Infarto miocardico (GISSI). Il protocollo dello studio GISSI-Prevenzione: Studio di intervento preventivo sulle componenti aterosclerotica e trombotica del rischio post-infarto.
G Ital Cardiol
 .
1993
;
23
:
1053
–1061
[42]
Meydani
M
, Natiello F, Goldin B, et al. Effect of long-term fish oil supplementation on vitamin E status and lipid peroxidation in women.
J Nutr
 .
1991
;
121
:
484
–491
[43]
Marchioli
R
. Antioxidant vitamins and prevention of cardiovascular disease: laboratory epidemiological, and clinical trial data.
Pharmacol Res
 .
1999
;
40
:
227
–238
[44]
Steinberg
D
, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity.
N Engl J Med
 .
1989
;
320
:
915
–924
[45]
Steinberg
D
. Antioxidants and atherosclerosis: a current assessment.
Circulation
 .
1991
;
84
:
1420
–1425
[46]
Steinberg
D
, workshop participants. Antioxidants in the prevention of human atherosclerosis.
Circulation
 .
1992
;
85
:
2337
–2344
[47]
Diaz
MN
, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease.
N Engl J Med
 .
1997
;
337
:
408
–416
[48]
The Alpha-TocopherolBeta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.
N Engl Med
 .
1994
;
330
:
1029
–1035
[49]
Stephens
NG
, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).
Lancet
 .
1996
;
347
:
781
–786
[50]
Mitchinson
MJ
, Stephens NG, Parsons A, Blight E, Schoefield PM, Brown MJ. Mortality in the CHAOS trial.
Lancet
 .
1999
;
353
:
381
[51]
Ness
A
, Davey Smith G. Mortality in the CHAOS trial.
Lancet
 .
1999
;
353
:
1017
–1018
[52]
Brown
M
. Do vitamin E and fish oil protect against ischaemic heart disease?
Lancet
 .
1999
;
354
:
441
–442
[53]
Rapola
JM
, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction.
Lancet
 .
1997
;
349
:
1715
–1720
[54]
Omenn
GS
. What accounts for the association of vegetables and fruit with lower incidence of cancers and coronary heart disease?
Ann Epidemiol
 .
1995
;
5
:
333
–335
[55]
Rimm
EB
, Stampfer MJ, Ascherio A, Giovannucci F, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men.
N Engl J Med
 .
1993
;
328
:
1450
–1456
[56]
Stampfer
MJ
, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women.
N Engl J Med
 .
1993
;
328
:
1444
–1449
[57]
Kushi
LH
, Folsom AR, Prineas RJ, et al. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women.
N Engl J Med
 .
1996
;
334
:
1156
–1162
[58]
Princen
HMG
, van Duyvenvoorde W, Buytenhek R, et al. Supplementation with low doses of vitamin E protects LDL from lipid peroxidation in men and women.
Arterioscler Thromb Vasc Biol
 .
1995
;
15
:
325
–333
[59]
Suzukawa
M
, Ishikawa T, Yoshida H, Nakamura K. Effect of in-vivo supplementation with low-dose vitamin E on susceptibility of low-density lipoprotein and high-density lipoprotein to oxidative modification.
J Am Coll Nutr
 .
1995
;
14
:
46
–52
[60]
Weber
P
, Bendich A, Machlin LJ. Vitamin E and human health: rationale for determining recommended intake levels.
Nutrition
 .
1997
;
13
:
450
–460
[61]
Porkkala-Sarataho
EK
, Nyyssonen MK, Kaikkonen JE, et al. A randomized, single-blind, placebo-controlled trial of the effects of 200 mg α-tocopherol on the oxidation resistance of atherogenic lipoproteins.
Am J Clin Nutr
 .
1998
;
68
:
1034
–1041
[62]
De Waart
FJ
, Moser U, Kok FJ. Vitamin E supplementation in elderly lowers the oxidation rate of linoleic acid in LDL.
Atherosclerosis
 .
1997
;
133
:
255
–263
[63]
GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.
Lancet
 .
1999
;
354
:
447
–455
[64]
Graziani
MS
, Ceriotti F, Carobene A, et al. Accuracy of cholesterol measurements in Italian clinical laboratories: joint project SIBioC GISSI-Prevenzione Italian Society of Biochemistry Group. on behalf of SIBioC GSSI-Prevenzione Group
Eur J Clin Chem Clin Biochem
 .
1997
;
35
:
311
–315
[65]
Stampfer
MJ
, Buring JE, Willett W, Rosner B, Eberlein K, Hennekens CH. The 2 × 2 factorial design: its applications to a randomized trial of aspirin and carotene in U.S. Physicians.
Stat Med
 .
1985
;
4
:
111
–116
[66]
Byar
DP
, Piantadosi S. Factorial designs for randomized clinical trials.
Cancer Treat Rep
 .
1985
;
69
:
1055
–1062
[67]
Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. Chichester, UK: John Wiley; 1995.
[68]
De Vita
C
, Franzosi MG, Geraci E, et al. GISSI-2 mortality plus extensive left ventricular damage as ‘end-points’.
Lancet
 .
1990
;
335
:
289
[69]
Dyerberg
J
, Bang HO, Stofferson E. Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis.
Lancet
 .
1978
;
ii
:
117
–119
[70]
Pietinen
P
, Ascerio A, Korhonen P, et al. Intake of fatty acids and risk of coronary heart disease in a cohort of Finish men: The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.
Am J Epidemiol
 .
1997
;
145
:
876
–887
[71]
Guallar
E
, Aro A, Jimenez FJ, et al. Omega-3 fatty acids in adipose tissue and risk of myocardial infarction: the EURAMIC study.
Arterioscler Thromb Vasc Biol
 .
1999
;
19
:
1111
–1118
[72]
Seidelin
KN
, Myrup B, Fischer-Hansen B. n-3 fatty acids in adipose tissue and coronary heart disease are inversely related.
Am J Clin Nutr
 .
1992
;
55
:
1117
–1119
[73]
The Long-Term Intervension with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med
 .
1988
;
339
:
1349
–1354
[74]
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet
 .
1994
;
344
:
1383
–1389
[75]
Antiplatelet Trialists' Collaboration. Secondary prevention of vascular events by prolonged antiplatelet therapy.
Br med J
 .
1988
;
296
:
320
–331
[76]
Sacks
FM
, Pfeffer MA, Moye LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med
 .
1996
;
335
:
1001
–1009
[77]
Fauchier
L
, Babuty D, Cosnay P, Fauchier JP. Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy.
J Am Coll Cardiol
 .
1999
;
33
:
1203
–1207
[78]
Marchioli
R
, Valagussa F. The results of the GISSI-Prevenzione trial in the general framework of secondary prevention. behalf of GISSI-Prevenzione Investigators
Eur Heart J
 .
2000
;
21
:
949
–952
[79]
De Caterina
R
, Cybulsky MI, Clinton SK, Gimbrone MA, Libby P. The omega-3 fatty acid decosahexanoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells.
Arterioscler Thromb
 .
1994
;
14
:
1829
–1836
[80]
Sacks
FM
, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP research group.
J Am Coll Cardiol
 .
1995
;
25
:
1492
–1498
[81]
Eritsland
J
, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency.
Am J Cardiol
 .
1996
;
77
:
31
–36
[82]
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction.
Lancet
 .
1990
;
336
:
65
–71
[83]
Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI). GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.
Lancet
 .
1994
;
343
:
1115
–1122
[84]
ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction.
Lancet
 .
1995
;
345
:
669
–685
[85]
Krauss
RM
, Eckel RH, Howard B, et al. AHA Dietary Guidelines Revision 2000: A Statement for Healthcare Professionals from the Nutrition Committee of the American Heart Association.
Circulation
 .
2000
;
102
:
2296
–2311